SCHEMBL204815

SCHEMBL204815

O=C(O)Cc1ccc(-c2csc(Nc3ccc(OC4CCCC4)c(C(F)(F)F)c3)n2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.42
P2RX3 P56373 1/20 0.40
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
CASP6 P55212 1/20 0.37
KMT2A Q03164 1/20 0.37
HDAC8 Q9BY41 2/20 0.37
VCP P55072 2/20 0.37
HDAC1 Q13547 1/20 0.37
NTSR1 P30989 1/20 0.37
CFTR P13569 2/20 0.36
SPHK2 Q9NRA0 2/20 0.36
SPHK1 Q9NYA1 2/20 0.36
CDK2 P24941 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
EPHX2 P34913 2/20 0.36
KDM4E B2RXH2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207262 0.87 PRMT5 (0.38) PRMT5WDR77MEN1POLBCASP6
SCHEMBL206298 0.82 XDH (0.41) PRMT5WDR77HDAC8VCPHDAC1
SCHEMBL206856 0.82 S1PR1 (0.49) PRMT5WDR77MEN1KMT2AHDAC8
SCHEMBL208337 0.81 S1PR1 (0.51) PRMT5WDR77MEN1KMT2AHDAC8
SCHEMBL206271 0.80 HDAC8 (0.43) PRMT5WDR77MEN1POLBKMT2A
SCHEMBL208437 0.79 HDAC8 (0.38) PRMT5WDR77MEN1KMT2AHDAC8
SCHEMBL206316 0.79 NTRK1 (0.39) PRMT5WDR77MEN1POLBKMT2A
SCHEMBL209137 0.78 S1PR1 (0.39) PRMT5WDR77MEN1POLBKMT2A
SCHEMBL206165 0.78 ALOX5 (0.49) P2RX3MEN1POLBKMT2AVCP
SCHEMBL205592 0.77 P2RX3 (0.42) RORCP2RX3MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 RORC 1412/4885P2RX3 2027/4885PRMT5 1987/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 RORC 1412/4885P2RX3 2027/4885PRMT5 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.